Clinical advances in hematology & oncology : H&O

publication venue for

Combined factor V and factor VIII deficiency: a report of a case, genetic analysis, and response to desmopressin acetate. 2012
Incidental discovery of an appendiceal carcinoid tumor and a renal cell carcinoma. 2003
Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.. 20 Suppl 9. 2022
Recent clinical trial data of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.. 20 Suppl 9. 2022
Should venetoclax be used with or without anti-CD20 therapy for CLL?. 19. 2021
Highlights in B-cell malignancies from the 61st American Society of Hematology Annual Meeting: commentary.. 18 Suppl 8. 2020
Insights into the increasing costs of cancer drugs.. 17. 2019
Frontline management of chronic lymphocytic leukemia.. 15 Suppl 10. 2017
Integrating current treatment options for TKI-resistant chronic myeloid leukemia.. 12. 2014
Transplantation remains significantly underused.. 12. 2014
Highlights in B-cell malignancies from the 2013 American Society of Hematology annual meeting and exposition: commentary.. 12 Suppl 8. 2014
Commentary.. 12. 2014
Highlights in T-cell lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition: commentary.. 12 Suppl 5. 2014
The role of tyrosine kinase inhibitors in hepatocellular carcinoma.. 12. 2014
Unmet needs in the treatment of chronic lymphocytic leukemia: introduction.. 12 Suppl 3. 2014
Emerging therapies in melanoma.. 10. 2012
Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.. 10. 2012
Antibody-drug conjugate technology development for hematologic disorders.. 10. 2012
Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?. 10. 2012
The need for postoperative radiation therapy.. 10. 2012
Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting.. 9. 2011
Tumor self-seeding in breast cancer.. 9. 2011
Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion.. 9. 2011
Omacetaxine: the FDA decision.. 9. 2011
Clinical roundtable monograph. The management of aggressive T-cell lymphoma: a discussion on transformed mycosis fungoides.. 8. 2010
Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.. 8. 2010
New agents in early clinical trials for CLL therapy.. 8. 2010
Clinical roundtable monograph. Current management and treatment of T-cell lymphoma: A multidisciplinary approach.. 8. 2010
Clinical roundtable monograph: Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion.. 8. 2010
Pazopanib in renal cell carcinoma.. 8. 2010
Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion.. 8. 2010
Lessons learned from the development of kinase inhibitors.. 7. 2009
The evolving role of axillary dissection.. 7. 2009
Antibody treatment in lymphoma.. 7. 2009
Ixabepilone and other epothilones: microtubule-targeting agents for metastatic breast cancer.. 7. 2009
Utility of brain FDG-PET in primary CNS lymphoma.. 6. 2008
New agents in hepatocellular carcinoma.. 6. 2008
Is reduced-intensity conditioning the standard of care in the transplant setting?. 6. 2008
Will radioimmunotherapy survive?. 5. 2007
Advances at the Center for Cancer Research at the National Cancer Institute's Medical Oncology Branch.. 5. 2007
Wall Street's perspective on oncology drug development.. 5. 2007
Update on the use of imatinib mesylate.. 3. 2005
Current treatment of myelofibrosis.. 3. 2005
Current management of hormone-refractory prostate cancer.. 2. 2004
Antibodies in the treatment of lymphoma.. 2. 2004
Cognitive functions in primary central nervous system lymphoma patients treated with chemotherapy and stem cell transplantation: preliminary findings.. 1. 2003
The clinical importance of prognostic markers in CLL.. 20. 2022
The future role of bispecific antibodies in lymphoma.. 20. 2022
PSMA-targeted therapy in prostate cancer.. 19. 2021
Looking ahead to new therapies in small cell lung cancer.. 16. 2018
Update on the biology and management of neuroendocrine prostate cancer.. 14. 2016
New antibodies in the treatment of lymphoma.. 4. 2006
Treatment of multiple myeloma with carfilzomib in patients with renal injury. 2013
Hodgkin's lymphoma in HIV: unusual presentations and improving outcomes. 2003
Highlights in lymphoma from the 2016 American Society of Hematology annual meeting and exposition: Commentary. 2017
Highlights in T-cell lymphoma from the 2011 American Society of Hematology Annual Meeting and Exposition. 2012
Peripheral T-cell lymphomas: diagnosis and treatment options. Proceedings from a live roundtable, August 17, 2011, Kauai, Hawaii. 2011
A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. 2007
Current treatment of peripheral T-cell lymphoma. 2011
Clinical development of kinase inhibitors for the treatment of differentiated thyroid cancer. 2011
The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer. 2009
Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma. 2008
New developments in the treatment of esophageal cancer. 2004
Refining the standard of care in immune thrombotic thrombocytopenic purpura. 2024
A narrative review of anti-SARS-CoV-2 vaccines and immune thrombocytopenia: be aware, but reassured. 2022
Are novel agents ready to assume the mantle in the frontline treatment of mantle cell lymphoma? 2021
Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach. 2020
Surveillance scanning in lymphoma. 2019
Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. 2016
Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma. 2016
Review of fetal and neonatal immune cytopenias. 2015
Hematopoietic transplant-associated thrombotic microangiopathy: case report and review of diagnosis and treatments. 2014
Smoldering multiple myeloma: pathophysiologic insights, novel diagnostics, clinical risk models, and treatment strategies. 2014
New frontiers and treatment paradigms for thyroid carcinoma. 2014
Targeted therapies for treatment of recurrent ovarian cancer. 2014
Clinical roundtable monograph: unmet needs in the treatment of chronic lymphocytic leukemia: integrating a targeted approach. 2014
Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens? 2013
Targeting bone physiology for the treatment of metastatic prostate cancer. 2013
Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. 2012
Diagnosis of atypical hemolytic uremic syndrome: a review of case studies. 2012
Chemotherapy and immunotherapy combination in advanced prostate cancer. 2012
Pancreatic cancer: the role of molecular markers in diagnosis and management. 2011
Amphiphysin autoimmunity in paraneoplastic neurologic disease. 2009
Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. 2009
Prostate cancer vaccines: maximizing a suboptimal immune response for improved outcome. 2007
Combination treatment approaches and novel therapies for lymphoma. 2007
Use of dose-dense chemotherapy in the management of breast cancer. 2006
The role of FDG-PET imaging in the management of lymphoma. 2004

VIVO Weill Cornell Medical College

Clinical advances in hematology & oncology : H&O Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)